TY  - JOUR
AU  - Teira, Ramón
AU  - Diaz-Cuervo, Helena
AU  - Aragão, Filipa
AU  - Castaño, Manuel
AU  - Romero, Alberto
AU  - Roca, Bernardino
AU  - Montero, Marta
AU  - Galindo, Maria José
AU  - Muñoz-Sánchez, Maria Jose
AU  - Espinosa, Nuria
AU  - Peraire, Joaquim
AU  - Martínez, Elisa
AU  - de la Fuente, Belén
AU  - Domingo, Pere
AU  - Deig, Elisabeth
AU  - Merino, María Dolores
AU  - Geijo, Paloma
AU  - Estrada, Vicente
AU  - Sepúlveda, María Antonia
AU  - García, Josefina
AU  - Berenguer, Juan
AU  - Currán, Adriá
PY  - 2022
DO  - 10.1007/s40121-022-00630-y
SN  - 2193-8229
UR  - http://hdl.handle.net/10668/21552
T2  - Infectious diseases and therapy
AB  - Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities...
LA  - en
KW  - Adverse events
KW  - Effectiveness
KW  - HIV
KW  - Time to discontinuation
KW  - Triple therapy
KW  - Two-drug combinations
KW  - Virologic failure
TI  - Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
TY  - research article
VL  - 11
ER  -